Drug development for metastatic castration-resistant prostate cancer - European Medical Journal

Continue

Drug development for metastatic castration-resistant prostate cancer

Oncology

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer Centre, Glasgow, UK, reviews the scientific and societal challenges of drug development for the treatment of patients with metastatic castration-resistant prostate cancer.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given